fluphenazine has been researched along with Dyskinesia, Drug-Induced in 130 studies
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To review the effects of fluphenazine and low-potency antipsychotics for people with schizophrenia." | 8.90 | Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. ( Engel, RR; Huhn, M; Leucht, S; Tardy, M, 2014) |
| " The dosage equivalency of haloperidol decanoate (1." | 6.66 | A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. ( Annable, L; Campbell, W; Chouinard, G, 1989) |
| "This study evaluated the feasibility and impact of gradually reducing relatively high doses of fluphenazine decanoate by one-half for chronically impaired, poor inner-city patients with schizophrenia." | 5.07 | A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. ( Egan, GJ; Gloersen, BA; Inderbitzin, LB; Lewine, RR; Scheller-Gilkey, G; Swofford, CD; Vidanagama, BP; Waternaux, C, 1994) |
| "In an attempt to begin to establish minimum effective dosage requirements for the maintenance treatment of schizophrenia, we undertook a double-blind comparison of low-dose fluphenazine decanoate (1." | 5.05 | Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. ( Kane, JM; Ramos-Lorenzi, J; Reardon, G; Rifkin, A; Sarantakos, S; Schiebel, D; Woerner, M, 1983) |
| "To review the effects of fluphenazine and low-potency antipsychotics for people with schizophrenia." | 4.90 | Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. ( Engel, RR; Huhn, M; Leucht, S; Tardy, M, 2014) |
| " For low dose, relapse rates are higher if treatment continues for a second year, if dosage is very low, or if patients are not stable." | 3.77 | Maintenance medication for schizophrenia: strategies for dose reduction. ( Schooler, NR, 1991) |
| " Following a reduction in the dose of antipsychotic medications, or their complete discontinuation, mesolimbic dopamine receptor supersensitivity could be reflected in rapid relapse of schizophrenic patients, the development of schizophrenic symptoms in patients with no prior history of schizophrenia, or in the necessity for ever-increasing doses of long-acting depot fluphenazine to maintain a remission." | 3.66 | Is there a limbic system equivalent of tardive dyskinesia? ( Davis, KL; Rosenberg, GS, 1979) |
| "Oral fluphenazine was given in fixed, randomized, double-blind doses (10, 20, or 30 mg/day) for 4 weeks to 72 inpatients with acute schizophrenic exacerbations." | 2.68 | Fluphenazine plasma levels, dosage, efficacy, and side effects. ( Cooper, TB; Levinson, DF; Lo, ES; Simpson, GM; Singh, H; Stephanos, MJ; Yadalam, K, 1995) |
| "During long-term treatment of schizophrenia with antipsychotic medication, side effects such as weight gain and tardive dyskinesia may develop, while other extrapyramidal side effects may continue." | 2.67 | Side effects during long-term treatment with depot antipsychotic medication. ( Cookson, JC, 1991) |
| "Eighty-six patients with acute psychotic exacerbations were treated with fixed dosage regimens of oral fluphenazine up to 10-30 mg/day in randomized, double-blind studies." | 2.67 | Acute dystonia during fixed-dose neuroleptic treatment. ( Friedman, E; Levinson, DF; Lo, ES; Simpson, GM; Singh, H, 1990) |
| " The dosage equivalency of haloperidol decanoate (1." | 2.66 | A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. ( Annable, L; Campbell, W; Chouinard, G, 1989) |
| " There was no significant difference in survival when the clinician was permitted to make a dosage adjustment up to 10 mg in the low-dose group and 50 mg in the higher-dose group when the patient demonstrated evidence of a symptomatic exacerbation." | 2.66 | Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. ( Lebell, M; Marder, SR; May, PR; McKenzie, J; Mintz, J; Van Putten, T, 1987) |
| "Fluphenazine-induced VCMs were not affected by a variety of selective opiate agonists administered intracerebroventricularly, but were potently suppressed by subcutaneous administration of the opiate antagonist naloxone." | 2.38 | The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia. ( Frydryszak, H; Polanski, E; Stoessl, AJ, 1993) |
| "The fluphenazine treatment produced VCMs in the majority of the treated rats (87% after 24 weeks)." | 1.34 | Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats. ( Braga, AL; Calixto, JB; Fachinetto, R; Ferreira, J; Paixão, MW; Pereira, RP; Puntel, RL; Rocha, JB; Villarinho, JG; Wagner, C, 2007) |
| " Vacuous chewing movements were also seen following chronic administration of fluphenazine decanoate." | 1.29 | Effects of neurotensin in a rodent model of tardive dyskinesia. ( Stoessl, AJ, 1995) |
| " Chronic administration of fluphenazine elicited vacuous chewing movements (VCMs) in the rat." | 1.29 | Effects of ethanol in a putative rodent model of tardive dyskinesia. ( Stoessl, AJ, 1996) |
| " The authors examined the possibilities of a pharmacokinetic effect of alprazolam on neuroleptic plasma levels and of a clinical effect of alprazolam." | 1.28 | Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates. ( Angrist, B; Cooper, T; Douyon, R; Peselow, E; Rotrosen, J, 1989) |
| "Four Cebus apella monkeys with persistent dyskinetic movements induced by earlier long-term administration of haloperidol were subjected to a trial of the dyskinesia-modifying effects of a novel dopamine autoreceptor agonist 3-PPP (3[3-hydroxyphenyl]-N-n-propyl-piperidine)." | 1.27 | Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias. ( Carlsson, A; Gunne, LM; Häggström, JE; Wikström, H, 1983) |
| "In ongoing studies of chronic administration of neuroleptics to monkeys (Cebus apella) and rats, the regional distribution of glutamic acid decarboxylase (GAD) and brain levels of homovanillic acid were examined." | 1.27 | Experimental tardive dyskinesia. ( Gunne, LM; Häggström, JE, 1985) |
| " Such variations have been attributed to individual metabolism, pharmacologic differences, and age--all of which may need careful consideration in prescribing an appropriate dosage regimen for a given patient." | 1.27 | Interpatient variations in antipsychotic therapy. ( Gershon, S; McIntyre, IM, 1985) |
| "Haloperidol was given first in doses of 1." | 1.27 | Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review. ( Domino, EF, 1985) |
| " Moreover pharmacokinetic data increasingly have been clinically applied." | 1.27 | Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. ( Knudsen, P, 1985) |
| "Since both tardive dyskinesia and Tourette's disease are thought to be caused by relative overactivity or supersensitivity of the dopamine system, their reversible appearance after long term dopamine receptor blockade by neuroleptics can be expected in susceptible individuals." | 1.26 | Tardive dyskinesia with Tourette-like syndrome. ( Patel, J; Pyke, J; Seeman, MV, 1981) |
| "281 newly admitted female schizophrenic patients were treated with high dosage fluphenazine decanoate intramuscularly, starting with 250 mg per injection together with antiparkinsonian and antidepressant drugs." | 1.26 | Follow-up study of 281 schizophrenic patients treated with high dosage fluphenazine decanoate. ( Nagy, C; Steiner, S, 1981) |
| " An individualized approach to the dosage of Fluphenazine decanoate must be practiced in conjunction with, and taking into account the time spent in treatment and the sex and age variables reported." | 1.26 | Drug monitoring at an Australia depot phenothiazine clinic. ( Hiep, A; Marriott, P, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 93 (71.54) | 18.7374 |
| 1990's | 27 (20.77) | 18.2507 |
| 2000's | 9 (6.92) | 29.6817 |
| 2010's | 1 (0.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nudelman, A | 1 |
| Gil-Ad, I | 1 |
| Shpaisman, N | 1 |
| Terasenko, I | 1 |
| Ron, H | 1 |
| Savitsky, K | 1 |
| Geffen, Y | 1 |
| Weizman, A | 1 |
| Rephaeli, A | 1 |
| Tardy, M | 1 |
| Huhn, M | 1 |
| Engel, RR | 1 |
| Leucht, S | 1 |
| Rajarethinam, R | 1 |
| Dziuba, J | 1 |
| Manji, S | 1 |
| Pizzuti, A | 1 |
| Lachover, L | 1 |
| Keshavan, M | 1 |
| Miller, DD | 1 |
| McCormick, SE | 2 |
| Stoessl, AJ | 8 |
| Putzhammer, A | 1 |
| Perfahl, M | 1 |
| Pfeiff, L | 1 |
| Ibach, B | 1 |
| Johann, M | 1 |
| Zitzelsberger, U | 1 |
| Hajak, G | 1 |
| Fachinetto, R | 1 |
| Villarinho, JG | 1 |
| Wagner, C | 1 |
| Pereira, RP | 1 |
| Puntel, RL | 1 |
| Paixão, MW | 1 |
| Braga, AL | 1 |
| Calixto, JB | 1 |
| Rocha, JB | 1 |
| Ferreira, J | 1 |
| Gibson, AC | 3 |
| Kane, JM | 3 |
| Smith, JM | 1 |
| Mukherjee, S | 1 |
| Rosen, AM | 1 |
| Cardenas, C | 1 |
| Varia, V | 1 |
| Olarte, S | 1 |
| Schiff, AA | 3 |
| Woerner, M | 2 |
| Weinhold, P | 1 |
| Wegner, J | 1 |
| Kinon, B | 1 |
| Bartels, M | 1 |
| Riffel, B | 1 |
| Stöhr, M | 1 |
| Waddington, JL | 2 |
| Cross, AJ | 1 |
| Gamble, SJ | 1 |
| Bourne, RC | 1 |
| Barnes, TR | 2 |
| Wiles, DH | 2 |
| Oyewumi, LK | 1 |
| Lapierre, YD | 1 |
| Gray, R | 1 |
| Batth, S | 1 |
| Gelfand, R | 1 |
| Siris, SG | 1 |
| Rifkin, A | 4 |
| Reardon, GT | 1 |
| November, M | 1 |
| Reardon, G | 1 |
| Sarantakos, S | 1 |
| Schiebel, D | 1 |
| Ramos-Lorenzi, J | 1 |
| Glazer, WM | 2 |
| Kovacic, B | 4 |
| Domino, EF | 4 |
| Häggström, JE | 3 |
| Gunne, LM | 4 |
| Carlsson, A | 1 |
| Wikström, H | 1 |
| Perényi, A | 1 |
| Arató, M | 1 |
| Bárány, S | 1 |
| Friedman, E | 2 |
| Gianutsos, G | 1 |
| Kuster, J | 1 |
| Fairbairn, AF | 1 |
| Rowell, FJ | 1 |
| Hui, SM | 1 |
| Hassanyeh, F | 1 |
| Robinson, AJ | 1 |
| Eccleston, D | 1 |
| Athanassenas, G | 1 |
| Papadopoulos, E | 1 |
| Kourkoubas, A | 1 |
| Tsitourides, S | 1 |
| Gabriel, J | 1 |
| Hoïdas, S | 1 |
| Frangos, E | 1 |
| Shear, MK | 1 |
| Frances, A | 2 |
| Weiden, P | 3 |
| Seeman, MV | 1 |
| Patel, J | 1 |
| Pyke, J | 1 |
| Rey, JM | 1 |
| Hunt, GE | 1 |
| Johnson, GF | 1 |
| Levine, J | 1 |
| Schooler, NR | 2 |
| Severe, J | 1 |
| Escobar, J | 1 |
| Gelenberg, A | 1 |
| Mandel, M | 1 |
| Sovner, R | 1 |
| Steinbook, R | 1 |
| McCreadie, RG | 1 |
| Dingwall, JM | 1 |
| Heykants, JJ | 1 |
| McCreadie, R | 1 |
| Mackie, M | 1 |
| Morrison, D | 1 |
| Kidd, J | 1 |
| Chouinard, G | 4 |
| Creese, I | 1 |
| Boisvert, D | 1 |
| Annable, L | 4 |
| Bradwejn, J | 1 |
| Jones, B | 1 |
| Russell, N | 1 |
| Landmark, J | 1 |
| Merskey, H | 1 |
| Turpin, T | 1 |
| Goldberg, SC | 1 |
| Shenoy, RS | 1 |
| Sadler, A | 1 |
| Hamer, R | 1 |
| Ross, B | 1 |
| Csernansky, JG | 1 |
| Grabowski, K | 1 |
| Cervantes, J | 1 |
| Kaplan, J | 1 |
| Yesavage, JA | 1 |
| Steiner, S | 1 |
| Nagy, C | 1 |
| Anderson, JA | 1 |
| Moore, DC | 1 |
| Munetz, MR | 2 |
| Parsons, B | 1 |
| Togasaki, DM | 1 |
| Kassir, S | 1 |
| Przedborski, S | 1 |
| Levinson, DF | 2 |
| Simpson, GM | 2 |
| Lo, ES | 3 |
| Cooper, TB | 2 |
| Singh, H | 2 |
| Yadalam, K | 1 |
| Stephanos, MJ | 1 |
| Rosengarten, H | 2 |
| Schweitzer, JW | 2 |
| Friedhoff, AJ | 2 |
| Gall, JA | 1 |
| Drummer, OH | 1 |
| Landgren, AJ | 1 |
| Polanski, E | 1 |
| Frydryszak, H | 1 |
| Bransgrove, LL | 1 |
| Kelly, MW | 1 |
| Inderbitzin, LB | 1 |
| Lewine, RR | 1 |
| Scheller-Gilkey, G | 1 |
| Swofford, CD | 1 |
| Egan, GJ | 1 |
| Gloersen, BA | 1 |
| Vidanagama, BP | 1 |
| Waternaux, C | 1 |
| Zahn, TP | 1 |
| Pickar, D | 1 |
| Haier, RJ | 1 |
| Shedlack, KJ | 1 |
| Soldato-Couture, C | 1 |
| Swanson, CL | 1 |
| Rajakumar, N | 1 |
| Wirshing, DA | 1 |
| Bartzokis, G | 1 |
| Pierre, JM | 1 |
| Wirshing, WC | 1 |
| Sun, A | 1 |
| Tishler, TA | 1 |
| Marder, SR | 3 |
| Sachdev, P | 3 |
| Saharov, T | 1 |
| Cathcart, S | 1 |
| Van Kampen, JM | 1 |
| Linn, GS | 2 |
| Lifshitz, K | 2 |
| O'Keeffe, RT | 2 |
| Lee, K | 1 |
| Camp-Lifshitz, J | 1 |
| Quitkin, F | 2 |
| Gochfeld, L | 1 |
| Klein, DF | 2 |
| Smith, RC | 1 |
| Strizich, M | 1 |
| Klass, D | 1 |
| Gardos, G | 1 |
| Cole, JO | 1 |
| La Brie, RA | 1 |
| Ross-Chouinard, A | 2 |
| Nestoros, JN | 1 |
| Kropsky, ML | 1 |
| Mattes, J | 1 |
| Davis, KL | 2 |
| Rosenberg, GS | 1 |
| Rabiner, CJ | 1 |
| Chien, CP | 1 |
| Castaldo, V | 1 |
| Thornton, A | 1 |
| Maltbie, A | 1 |
| Jose, C | 1 |
| Mallya, A | 1 |
| Mehta, D | 1 |
| Evenson, R | 1 |
| Holland, R | 1 |
| Nasrallah, HA | 1 |
| Freeman, H | 1 |
| Wiles, D | 1 |
| Marriott, P | 2 |
| Hiep, A | 1 |
| Owens, D | 1 |
| Grunhaus, L | 1 |
| Sancovici, S | 1 |
| Rimon, R | 1 |
| Marcjan, K | 1 |
| Pietruszewska, I | 1 |
| Wolak, E | 1 |
| Pfefferbaum, A | 1 |
| Berger, PA | 2 |
| De Fraites, EG | 1 |
| Albanese, H | 1 |
| Gaardner, K | 1 |
| Ayd, FJ | 1 |
| Soni, SD | 1 |
| Sampath, G | 1 |
| Shah, A | 1 |
| Krska, J | 1 |
| Bergen, J | 1 |
| Kitchin, R | 1 |
| Berry, G | 1 |
| Tang, WM | 1 |
| Mitchell, IJ | 1 |
| Crossman, AR | 1 |
| Liminga, U | 1 |
| Andren, P | 1 |
| McClelland, HA | 1 |
| Metcalfe, AV | 1 |
| Kerr, TA | 1 |
| Dutta, D | 1 |
| Watson, P | 1 |
| Szczutkowski, E | 1 |
| Cookson, JC | 1 |
| Lee, KL | 1 |
| Mase, D | 1 |
| Avery, J | 1 |
| Midha, KK | 1 |
| Van Putten, T | 2 |
| Aravagiri, M | 2 |
| Hawes, EM | 1 |
| Hubbard, JW | 1 |
| McKay, G | 1 |
| Mintz, J | 2 |
| Boyer, P | 1 |
| Lecrubier, Y | 1 |
| Puech, AJ | 1 |
| See, RE | 3 |
| Ellison, GD | 2 |
| Douyon, R | 1 |
| Angrist, B | 1 |
| Peselow, E | 1 |
| Cooper, T | 1 |
| Rotrosen, J | 1 |
| Jann, MW | 1 |
| Fidone, GS | 1 |
| Hernandez, JM | 1 |
| Amrung, S | 1 |
| Davis, CM | 1 |
| Campbell, W | 1 |
| Faraone, SV | 1 |
| Green, AI | 1 |
| Brown, W | 1 |
| Yin, P | 1 |
| Tsuang, MT | 1 |
| Neehall, J | 1 |
| Cooper, SJ | 1 |
| Doherty, MM | 1 |
| King, DJ | 1 |
| Weinstein, D | 1 |
| Ellison, G | 1 |
| Klawans, HL | 1 |
| Carvey, P | 1 |
| Tanner, CM | 1 |
| Goetz, CG | 1 |
| McIntyre, IM | 1 |
| Gershon, S | 1 |
| Johnson, DA | 1 |
| Kolakowska, T | 3 |
| Williams, AO | 3 |
| Ardern, M | 3 |
| Knudsen, P | 1 |
| Reveley, MA | 1 |
| Scrak, BM | 1 |
| Greenstein, RA | 1 |
| Levy, AD | 1 |
| Levin, ED | 1 |
| Genz, A | 1 |
| Galdi, J | 1 |
| Bonato, RR | 1 |
| Egawa, M | 1 |
| Yassa, R | 1 |
| Iskandar, H | 1 |
| Ally, J | 1 |
| Pajari, KL | 1 |
| Le Witt, P | 1 |
| Clark, D | 1 |
| Ginchereau, EH | 1 |
| Toenniessen, LM | 1 |
| Lebell, M | 1 |
| McKenzie, J | 1 |
| May, PR | 1 |
| Harrigan, M | 1 |
| Curson, DA | 1 |
| Bamber, RW | 1 |
| Platt, SD | 1 |
| Hirsch, SR | 1 |
| Duffy, JC | 1 |
| Cadieux, RJ | 1 |
| Kales, JD | 1 |
| Kales, A | 1 |
| Biever, J | 1 |
| Mann, LD | 1 |
| Rapisarda, V | 1 |
| Bonomo, V | 1 |
| Parisi, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588] | Phase 4 | 60 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/L (Mean) |
|---|---|
| Pravastatin | 0.8063 |
| Placebo | -0.5136 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/dl (Mean) |
|---|---|
| Pravastatin | -25.565 |
| Placebo | -2.913 |
"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | 4.0417 |
| Placebo | 4.125 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -5.625 |
| Placebo | -3.76 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -0.83 |
| Placebo | -0.28 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -2.9583 |
| Placebo | -2.44 |
The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -9.416 |
| Placebo | -6.48 |
6 reviews available for fluphenazine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Dyskinesia, Drug-Induced; Fluphenazine; Humans; Rando | 2014 |
Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Antipsychotic Agents; Delayed-Action Preparations; D | 1982 |
Depot fluphenazine: risk/benefit ratio.
Topics: Administration, Oral; Basal Ganglia Diseases; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Fe | 1984 |
The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; Fluphenazine; Locomotion; Male; Mastication | 1993 |
Maintenance medication for schizophrenia: strategies for dose reduction.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Fluphenazine; Humans; Schizophrenia | 1991 |
Antipsychotic medication: clinical guidelines for maintenance therapy.
Topics: Administration, Oral; Ambulatory Care; Anti-Anxiety Agents; Antipsychotic Agents; Basal Ganglia Dise | 1985 |
24 trials available for fluphenazine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Performance of diadochokinetic movements in schizophrenic patients.
Topics: Analysis of Variance; Antipsychotic Agents; Biomechanical Phenomena; Case-Control Studies; Dose-Resp | 2005 |
Comparative side effects of imipramine, benztropine, or their combination in patients receiving fluphenazine decanoate.
Topics: Adult; Benztropine; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Drug Therapy | 1983 |
Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.
Topics: Adult; Ambulatory Care; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; | 1983 |
Depot fluphenazine: risk/benefit ratio.
Topics: Administration, Oral; Basal Ganglia Diseases; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Fe | 1984 |
Serum calcium and magnesium levels in chronic schizophrenics.
Topics: Calcium; Chronic Disease; Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Loxapine; Magnesiu | 1983 |
Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Delayed-Action Preparations; Dyskinesia, Drug | 1980 |
Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
Topics: Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Fluphenazi | 1980 |
Fluphenazine plasma levels, dosage, efficacy, and side effects.
Topics: Acute Disease; Administration, Oral; Adult; Akathisia, Drug-Induced; Basal Ganglia Diseases; Dose-Re | 1995 |
A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Topics: Adult; Ambulatory Care; Basal Ganglia Diseases; Chronic Disease; Delayed-Action Preparations; Double | 1994 |
Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia.
Topics: Adult; Attention; Auditory Perception; Clozapine; Dominance, Cerebral; Dyskinesia, Drug-Induced; Fem | 1994 |
Tardive dyskinesia and serum iron indices.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Ferritins; Fluphenazine; | 1998 |
Ethopropazine and benztropine in neuroleptic-induced parkinsonism.
Topics: Adult; Benztropine; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; | 1979 |
Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year.
Topics: Acute Disease; Administration, Oral; Aftercare; Chronic Disease; Clinical Trials as Topic; Dyskinesi | 1977 |
Maintenance medication for schizophrenia: strategies for dose reduction.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Fluphenazine; Humans; Schizophrenia | 1991 |
Side effects during long-term treatment with depot antipsychotic medication.
Topics: Akathisia, Drug-Induced; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; | 1991 |
Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
Topics: Adult; Akathisia, Drug-Induced; Delayed-Action Preparations; Dose-Response Relationship, Drug; Doubl | 1991 |
Treatment of positive and negative symptoms: pharmacologic approaches.
Topics: Adult; Amisulpride; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug | 1990 |
Acute dystonia during fixed-dose neuroleptic treatment.
Topics: Adult; Amobarbital; Chloral Hydrate; Dose-Response Relationship, Drug; Drug Administration Schedule; | 1990 |
A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Clinical Trials as Topic; Delayed-Ac | 1989 |
Neuroleptic dose reduction in persistently psychotic patients.
Topics: Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Fluph | 1989 |
Tardive dystonia. The benefits of time.
Topics: Adult; Chlorpromazine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Dys | 1989 |
Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics.
Topics: Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; Depressive Disorder; Double-Blind Me | 1988 |
Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome.
Topics: Adult; Akathisia, Drug-Induced; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Indu | 1987 |
Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Dys | 1985 |
102 other studies available for fluphenazine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Catalepsy; Dextroamphe | 2008 |
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Sch | 2009 |
Clozapine and tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Fema | 2003 |
Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug | 2003 |
Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats.
Topics: Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Benzene Derivatives; Disease Models, | 2007 |
Incidence of tardive dyskinesia in patients receiving depot neuroleptic injection.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Female; Flupenthixol; F | 1981 |
Tardive dyskinesia in psychiatric outpatients: a study of prevalence and association with demographic, clinical, and drug history variables.
Topics: Age Factors; Ambulatory Care; Antipsychotic Agents; Delayed-Action Preparations; Delusions; Dentures | 1982 |
Fluphenazine decanoate and tardive dyskinesia.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Fluphenazine; Humans | 1982 |
A prospective study of tardive dyskinesia development: preliminary results.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Fem | 1982 |
[Tardive dystonia: a rare side effect after long-term neuroleptic treatment].
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Flupenth | 1982 |
Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; Fluphenazine; Haloper | 1983 |
Variation in oro-facial tardive dyskinesia during depot antipsychotic drug treatment.
Topics: Aged; Antipsychotic Agents; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Female; Fluphenaz | 1983 |
Abnormal involuntary movements in patients on long-acting neuroleptics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cross-Sectional Studies; Dose-Response Relationship, | 1983 |
Fluphenazine-induced acute and tardive dyskinesias in monkeys.
Topics: Animals; Behavior, Animal; Cebus; Dyskinesia, Drug-Induced; Female; Fluphenazine; Parasympatholytics | 1984 |
Monkey models of tardive dyskinesia.
Topics: Animals; Benztropine; Biperiden; Cebus; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Fl | 1983 |
Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias.
Topics: Animals; Cebus; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Fluphenazine; Ha | 1983 |
Fluphenazine and tardive dyskinesia.
Topics: Delayed-Action Preparations; Drug Administration Schedule; Dyskinesia, Drug-Induced; Fluphenazine; H | 1984 |
Application of a primate model for tardive dyskinesia.
Topics: Animals; Cebus; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Fluphenazine; Histamine An | 1983 |
Chronic fluphenazine and clozapine elicit opposite changes in brain muscarinic receptor binding: implications for understanding tardive dyskinesia.
Topics: Animals; Brain; Cerebral Cortex; Choline O-Acetyltransferase; Clozapine; Corpus Striatum; Dibenzazep | 1983 |
Serum concentration of depot neuroleptics in tardive dyskinesia.
Topics: Dyskinesia, Drug-Induced; Female; Flupenthixol; Fluphenazine; Humans; Male; Middle Aged; Schizophren | 1983 |
Suicide associated with akathisia and depot fluphenazine treatment.
Topics: Adult; Akathisia, Drug-Induced; Dyskinesia, Drug-Induced; Fluphenazine; Humans; Male; Psychomotor Ag | 1983 |
A monkey model of tardive dyskinesia (TD): evidence that reversible TD may turn into irreversible TD.
Topics: Animals; Cebus; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Stre | 1982 |
Tardive dyskinesia with Tourette-like syndrome.
Topics: Adult; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Receptor | 1981 |
Assessment of tardive dyskinesia in psychiatric outpatients using a standardized rating scale.
Topics: Adolescent; Adult; Age Factors; Aged; Ambulatory Care; Cross-Sectional Studies; Dyskinesia, Drug-Ind | 1981 |
Assessment of tardive dyskinesia in psychiatric outpatients using a standardized rating scale.
Topics: Adolescent; Adult; Age Factors; Aged; Ambulatory Care; Cross-Sectional Studies; Dyskinesia, Drug-Ind | 1981 |
Assessment of tardive dyskinesia in psychiatric outpatients using a standardized rating scale.
Topics: Adolescent; Adult; Age Factors; Aged; Ambulatory Care; Cross-Sectional Studies; Dyskinesia, Drug-Ind | 1981 |
Assessment of tardive dyskinesia in psychiatric outpatients using a standardized rating scale.
Topics: Adolescent; Adult; Age Factors; Aged; Ambulatory Care; Cross-Sectional Studies; Dyskinesia, Drug-Ind | 1981 |
Tardive dyskinesia, fluphenazine decanoate, and haloperidol.
Topics: Dyskinesia, Drug-Induced; Fluphenazine; Haloperidol; Humans | 1982 |
Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
Topics: Adult; Aged; Chronic Disease; Double-Blind Method; Dyskinesia, Drug-Induced; Fluphenazine; Humans; M | 1982 |
High neuroleptic plasma levels in patients manifesting supersensitivity psychosis.
Topics: Adult; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Male; Mi | 1982 |
A double-blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia.
Topics: Adult; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Fluphenazine; Fluspirilene; Humans; Ma | 1982 |
The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics [proceedings].
Topics: Adult; Dyskinesia, Drug-Induced; Fluphenazine; Humans; Recurrence; Schizophrenia | 1981 |
Fluphenazine decanoate and tardive dyskinesia: a possible association.
Topics: Adult; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Mal | 1981 |
Follow-up study of 281 schizophrenic patients treated with high dosage fluphenazine decanoate.
Topics: Age Factors; Dyskinesia, Drug-Induced; Female; Fluphenazine; Follow-Up Studies; Humans; Recurrence; | 1981 |
More on drug history and tardive dyskinesia.
Topics: Dyskinesia, Drug-Induced; Fluphenazine; Humans; Research Design; Statistics as Topic | 1980 |
The diagnosis of rapid abnormal involuntary movements associated with fluphenazine decanoate.
Topics: Benztropine; Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Male; Middle Aged; Schizophreni | 1980 |
Oculogyric crises and tardive dyskinesia.
Topics: Dyskinesia, Drug-Induced; Fixation, Ocular; Fluphenazine; Humans; Male; Middle Aged | 1980 |
Effects of neurotensin in a rodent model of tardive dyskinesia.
Topics: Animals; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Fluphenazine; | 1995 |
Neuroleptics up-regulate adenosine A2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Binding Sites; Binding, Competitive; Corpus Striatum; Dyskinesia, Dru | 1995 |
Possible genetic factors underlying the pathophysiology of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Apomorphi | 1994 |
Death due to benzhexol toxicity.
Topics: Bronchopneumonia; Cause of Death; Death, Sudden; Dyskinesia, Drug-Induced; Empyema, Pleural; Fatal O | 1995 |
Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Female; Fluphenazine; | 1994 |
Rapidly progressive tardive dyskinesia in AIDS.
Topics: Adult; AIDS Dementia Complex; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Fluphenazine; H | 1994 |
Effects of ethanol in a putative rodent model of tardive dyskinesia.
Topics: Affinity Labels; Animals; Antipsychotic Agents; Azides; Behavior, Animal; Benzodiazepines; Central N | 1996 |
Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Dyskinesia, Drug-Induced; Fluphenazine; Male; Motor | 1996 |
The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia.
Topics: Animals; Antioxidants; Antipsychotic Agents; Delayed-Action Preparations; Disease Models, Animal; Dy | 1999 |
Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Behavior, | 2000 |
Increased incidence of dyskinesias and other behavioral effects of re-exposure to neuroleptic treatment in social colonies of Cebus apella monkeys.
Topics: Aggression; Animals; Antipsychotic Agents; Cebus; Dyskinesia, Drug-Induced; Female; Fluphenazine; Lo | 2001 |
Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia.
Topics: Animals; Dose-Response Relationship, Drug; Dynorphins; Dyskinesia, Drug-Induced; Fluphenazine; Globu | 2002 |
Tardive dyskinesia: are first signs reversible?
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Dyskinesia, Drug-Induced; Female; Fluphenazine; Haloper | 1977 |
Drug history and tardive dyskinesia.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Dr | 1978 |
Drug variables in the etiology of tardive dyskinesia application of discriminant function analysis.
Topics: Adult; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Male; Mid | 1977 |
Factors related to tardive dyskinesia.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Fluphenazine; Foll | 1979 |
Statistical shortcomings?
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Fluphenazine; Huma | 1979 |
Is there a limbic system equivalent of tardive dyskinesia?
Topics: Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Fluphenaz | 1979 |
Prophylactic usage of antiparkinsonian drugs for akinesia [proceedings].
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Fluphenazine; Humans | 1979 |
Iatrogenic morbidity in patients taking depot fluphenazine.
Topics: Adult; Age Factors; Aged; Akathisia, Drug-Induced; Basal Ganglia Diseases; Delayed-Action Preparatio | 1979 |
Tardive dyskinesia and depot fluphenazine.
Topics: Dyskinesia, Drug-Induced; Fluphenazine; Humans; Substance Withdrawal Syndrome | 1979 |
Pimozide as a neuroleptic.
Topics: Delusions; Dyskinesia, Drug-Induced; Flupenthixol; Fluphenazine; Humans; Pimozide; Schizophrenia | 1979 |
Tardive dyskinesia and depot fluphenazine.
Topics: Delayed-Action Preparations; Dyskinesia, Drug-Induced; Fluphenazine; Humans; Time Factors | 1979 |
Drug monitoring at an Australia depot phenothiazine clinic.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Australia; Chronic Disease; Decanoates; Delayed-Acti | 1978 |
The use of fluphenazines in a continuing-care program.
Topics: California; Chronic Disease; Continuity of Patient Care; Delayed-Action Preparations; Drug Administr | 1978 |
Depot fluphenazine and tardive dyskinesia.
Topics: Delayed-Action Preparations; Dyskinesia, Drug-Induced; Fluphenazine; Humans | 1978 |
Depot injections and tardive dyskinesia.
Topics: Chorea; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Female; Flupenthixol; Fluphenazine; H | 1978 |
Depot injections and tardive dyskinesia.
Topics: Delayed-Action Preparations; Dyskinesia, Drug-Induced; Fluphenazine; Humans; Hysteria | 1979 |
Neuroleptic malignant syndrome due to depot fluphenazine.
Topics: Adult; Coma; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Fever; Fluphenazine; Humans; Mal | 1979 |
[Results of the use of fluphenazine in a depot preparation].
Topics: Adolescent; Adult; Bipolar Disorder; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Female; | 1975 |
Narcolepsy, paranoid psychosis, and tardive dyskinesia: a pharmacological dilemma.
Topics: Chlorpromazine; Dyskinesia, Drug-Induced; Fluphenazine; Humans; Imipramine; Male; Middle Aged; Narco | 1977 |
Coexisting tardive dyskinesia and parkinsonism: a case report.
Topics: Acetylcholine; Adult; Benztropine; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Fluphenazine | 1977 |
Biofeedback treatment of tardive dyskinesia: two case reports.
Topics: Adult; Biofeedback, Psychology; Dyskinesia, Drug-Induced; Fluphenazine; Humans; Male; Masticatory Mu | 1977 |
Therapy with injectable fluphenazines.
Topics: Acute Disease; Age Factors; Ambulatory Care; Basal Ganglia Diseases; Chronic Disease; Delayed-Action | 1976 |
Psychophamacological treatment.
Topics: Delayed-Action Preparations; Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Injections; Mal | 1976 |
Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation.
Topics: Administration, Oral; Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Dyskinesia, | 1992 |
Predictors of the course of tardive dyskinesia in patients receiving neuroleptics.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; F | 1992 |
Psychotic symptoms preceding ocular deviation in a patient with tardive oculogyric crises.
Topics: Adult; Antipsychotic Agents; Benztropine; Chlorpromazine; Dose-Response Relationship, Drug; Dyskines | 1992 |
Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the Cebus monkey.
Topics: Animals; Autoradiography; Blood Glucose; Brain; Brain Mapping; Cebus; Densitometry; Deoxyglucose; Dy | 1992 |
Facial dyskinesia: a 16-year follow-up study.
Topics: Affective Disorders, Psychotic; Aged; Antipsychotic Agents; Brain; Chlorpromazine; Dose-Response Rel | 1991 |
Neurotensin and neurotensin analogues modify the effects of chronic neuroleptic administration in the rat.
Topics: Animals; Antipsychotic Agents; Drug Synergism; Dyskinesia, Drug-Induced; Fluphenazine; Injections, I | 1991 |
Effect of extended depot fluphenazine treatment and withdrawal on social and other behaviors of Cebus apella monkeys.
Topics: Animals; Behavior, Animal; Cebus; Dyskinesia, Drug-Induced; Electroencephalography; Female; Fluphena | 1991 |
Tardive oculogyric crisis and obsessional thoughts.
Topics: Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Middle Aged; Obsessive-Compulsive Disorder; | 1991 |
Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors.
Topics: Animals; Autoradiography; Behavior, Animal; Benzazepines; Brain; Disease Models, Animal; Dyskinesia, | 1989 |
Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
Topics: Adult; Alprazolam; Antipsychotic Agents; Basal Ganglia Diseases; Drug Synergism; Drug Therapy, Combi | 1989 |
Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; F | 1989 |
Tardive dyskinesia in outpatients on depot phenothiazine.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Delayed-Action Preparations; | 1989 |
Delayed appearance of facial tics following chronic fluphenazine administration to guinea pigs.
Topics: Animals; Dextroamphetamine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Dr | 1989 |
The pathophysiology of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Chlorpromazine; Corpus Striatum; Disea | 1985 |
Experimental tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Brain; Cebus; Corpus Striatum; Disease Models, Animal; Drug Evaluatio | 1985 |
Interpatient variations in antipsychotic therapy.
Topics: Age Factors; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dose-Response Relationshi | 1985 |
Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review.
Topics: Animals; Antipsychotic Agents; Benztropine; Cebus; Death, Sudden; Disease Models, Animal; Drug Thera | 1985 |
Tardive dyskinesia and current dose of neuroleptic drugs.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Flupenthixo | 1985 |
Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations.
Topics: Administration, Oral; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response | 1985 |
Tardive dyskinesia in schizophrenics under 60 years of age.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Dyskinesia, Drug-Ind | 1986 |
Tardive dyskinesia and current dose of neuroleptic drugs.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Fluphenazine; Humans | 1986 |
Tardive dyskinesia. Evaluation in a nurse managed prolixin program.
Topics: Adult; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Injection | 1986 |
Neuroleptic-induced oral movements in rats: methodological issues.
Topics: Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Fluphenazine; Haloperidol; Methods; | 1987 |
[Tardive dystonia--a case report on therapy and metaphylaxis].
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Fluphena | 1988 |
Diminished D2 dopamine receptor function and the emergence of repetitive jaw movements.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Disease Models, A | 1988 |
The prevalence of tardive dyskinesia in fluphenazine-treated patients.
Topics: Aging; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Male; Middle Ag | 1988 |
Persistence of neuroleptic drugs in plasma and body tissue.
Topics: Adult; Dyskinesia, Drug-Induced; Fluphenazine; Humans; Male; Metabolic Clearance Rate; Schizophrenia | 1988 |
Suppression of neuroleptic-induced persistent abnormal movements in Cebus apella monkeys by enantiomers of 3-PPP.
Topics: Animals; Cebus; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Fluphenazine; Pi | 1988 |
Tardive dyskinesia complicated by hyperthyroidism.
Topics: Adult; Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Psychotic Disorders; Thyrotoxicosis | 1987 |
Promoting compliance with outpatient drug treatment.
Topics: Adult; Benztropine; Dyskinesia, Drug-Induced; Female; Fluphenazine; Humans; Patient Compliance; Schi | 1987 |
A clinical guide for diagnosing and managing patients with drug-induced dysphagia.
Topics: Aged; Deglutition Disorders; Dyskinesia, Drug-Induced; Female; Fluphenazine; Food, Formulated; Human | 1986 |
Pharmacologic and psychotherapeutic issues in coexistent paranoid schizophrenia and narcolepsy: case report.
Topics: Adaptation, Psychological; Adult; Combined Modality Therapy; Dyskinesia, Drug-Induced; Fluphenazine; | 1985 |
Long-acting therapy of schizophrenia.
Topics: Adolescent; Adult; Antiparkinson Agents; Benzodiazepines; Biofeedback, Psychology; Bromocriptine; Dy | 1985 |